SuperGen Presentations at AACR-NCI-EORTC
* Reuters is not responsible for the content in this press release.
http://www.businesswire.com/news/home/20091109005409/en
DUBLIN, Calif.--(Business Wire)--
SuperGen, Inc. (Nasdaq:SUPG), a pharmaceutical company dedicated to the
discovery and development of novel cancer therapies, today announced the
acceptance of seven abstracts for poster presentations on November 16, 17 and
18, 2009 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics
conference in Boston, MA.
SuperGen`s presentations will review clinical and non-clinical advances in the
following compounds: MP-470, SGI-1776, SGI-110, SGI-1252, as well as two
presentations on the Etk program. The posters will be made available for viewing
on the company`s website www.supergen.com following the respective
presentations.
MP-470: The tyrosine kinase inhibitor MP470 inhibits RAD51-mediated homologous recombination and increases tumor cell radio- and chemosensitivity
Abstract A122, Monday Nov 16, 12:30 - 2:30 pm EST
SGI-110: In vivo activity of SGI-110, a novel hypomethylating agent for treatment in hematology and solid malignancies
Abstract A190, Monday Nov 16, 12:30 - 2:30 pm EST
MP-470: A self-emulsifying lipid suspension formulation enhances oral bioavailability of MP-470 in a randomized two-way crossover study in healthy male subjects
Abstract B209, Tuesday Nov 17, 12:30 - 2:30 pm EST
SGI-1776: The novel PIM kinase inhibitor SGI-1776 significantly enhances the preclinical activity of sunitinib in renal cell carcinoma
Abstract B272, Tuesday Nov 17, 12:30 - 2:30 pm EST
ETK/BMX: Mechanistic, functional and in vivo efficacy of inhibiting ETK/BMX in cancer models
Abstract B263, Tuesday Nov 17, 12:30 - 2:30 pm EST
SGI-1252: In vivo activity of SGI-1252, a potent, small-molecule dual inhibitor of JAK2 and ALK2
Abstract C206, Wednesday Nov 18, 12:30 - 2:30 pm EST
ETK: Development of potent, small-molecule inhibitors of ETK
Abstract C199 Wednesday Nov 18, 12:30 - 2:30 pm EST
About SuperGen
SuperGen is a pharmaceutical company dedicated to the discovery and development
of novel cancer therapeutics in epigenetic and cell signaling modulation. The
Company develops products through biochemical and clinical proof of concept to
partner for further development and commercialization. For more information
about SuperGen, please visit http://www.supergen.com.
SuperGen, Inc.
Timothy L. Enns, 925-560-2810
Senior Vice President
Corporate Communications & Business Development
tenns@supergen.com
Susanna Chau, 925-560-2845
Manager
Investor Relations
schau@supergen.com
Copyright Business Wire 2009
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters